Kedrion-Kamada, Anti-COVID IG development update
Watch the interview given to LeFontiTV by the CEO of our partner Kamada
Rh&Life, first subject included in the study
Two hundred pregnant women to be enrolled over five countries
Updates on anti-COVID treatment developed by Kamada and Kedrion
Top-line results announced from the phase 1/2 clinical trial in Israel
CARES10 Clinical Trial: last patient treated in the USA
Study to assess efficacy, safety and pharmacokinetics of a 10 percent Immunoglobulin in PI patients.
Plasma collection, a key step towards Self-Sufficiency in Italy
Paolo Marcucci participates in the Risk Management Forum in Arezzo
Kedrion supports Humanitarian Donation of Factor VIII in Palestine
More accessible treatments: the company continues its commitment, even in the thick of the pandemic
Kedrion supports new FVIII donation from Italy to El Salvador
A total amount of 3.5 million units manufactured from national plasma made available by the Region of Emilia-Romagna
Kedrion Supports Factor VIII Donation from Italy to El Salvador
Product manufactured from national plasma was made available by the Region of Sicily
Humanitarian Factor IX donation to Afghanistan
Kedrion Biopharma confirms its commitment to broaden access to therapies in developing Countries
Project PODs on plasma-derived orphan drugs takes the center stage at SMAU
Kedrion Biopharma and the CNR of Pisa participated in Toscana Technologica on 14-15 July 2015 in Florence
